Replimune, Inc.

Contributing Author

Recent Articles by Replimune, Inc.

1 hour	Replimune Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update REPL GlobeNewswire
Oct-20	Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma REPL GlobeNewswire
Oct-19	Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025 REPL GlobeNewswire
Sep-18	Replimune Provides Update Following Type A Meeting with FDA REPL GlobeNewswire
Sep-02	Replimune Announces Type A Meeting Scheduled with FDA REPL GlobeNewswire
Aug-07	Replimune Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate Update REPL GlobeNewswire
Jul-22	Replimune Receives Complete Response Letter from FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma REPL GlobeNewswire
Jul-11	Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) REPL GlobeNewswire